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Tildipirosin, a 16-membered-ring macrolide antimicrobial, has recently been approved
for the treatment of swine respiratory disease and bovine respiratory disease. This
macrolide is extensively distributed to the site of respiratory infection followed by
slow elimination. Clinical efficacy has been demonstrated in cattle and swine clinical
field trials. However, the pharmacokinetic/pharmacodynamic (PK/PD) index that best
correlates with the efficacy of tildipirosin remains undefined. The objective of this study
was to develop a PK/PD model following subcutaneous injection of tildipirosin against
Pasteurella multocida in a murine lung infection model. The PK studies of unbound (f )
tildipirosin in plasma were determined following subcutaneous injection of single doses
of 1, 2, 4, 6, and 8 mg/kg of body weight in neutropenic lung-infected mice. The
PD studies were conducted over 24 h based on twenty intermittent dosing regimens,
of which total daily dose ranged from 1 to 32 mg/kg and dosage intervals included
6, 8, 12, and 24 h. The minimum inhibitory concentration (MIC) of tildipirosin against
P. multocida was determined in serum. The inhibitory effect Imax model was employed
for PK/PD modeling. The area under the unbound concentration-time profile over 24 h
to MIC (fAUC0−24 h/MIC) was the PK/PD index that best described the antibacterial
activity in the murine infection model. The fAUC0−24 h/MIC targets required to achieve
the bacteriostatic action, a 1-log10 kill and 2-log10 kill of bacterial counts were 19.93,
31.89, and 53.27 h, respectively. These results can facilitate efforts to define more
rational designs of dosage regimens of tildipirosin using classical PK/PD concepts for
the treatment of respiratory diseases in pigs and cattle.
Keywords: tildipirosin, pharmacokinetic/pharmacodynamic (PK/PD), murine lung infection model, Pasteurella
multocida, minimum inhibitory concentration (MIC)
INTRODUCTION
Bovine respiratory disease (BRD) is the most common and costly disease of feedlot cattle
in the world (Snowder et al., 2006; Gay and Barnouin, 2009). The infection usually involves
stress from transportation, fatigue, anxiety, or viral infections combined with one or more
bacterial pathogens (Rose et al., 2012). The bacterial agents most commonly linked to BRD are
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Mannheimia haemolytica, Pasteurella multocida, Histophilus
somni, and Mycoplasma bovis (Snowder et al., 2006; Watts and
Sweeney, 2010). Swine respiratory disease (SRD) constitutes
some of the most important diseases of growing pigs and results
in substantial economic loss and reduced welfare (Sørensen
et al., 2006). Although these infections can be treated with
one of several groups of antibiotics, effective treatment of these
bacteria may be challenging because of antimicrobial resistance
and limited therapeutic options (Lockwood et al., 2003; Godinho
et al., 2005; Magstadt et al., 2018).
Tildipirosin is a semi-synthetic derivative of the naturally
occurring 16-membered macrolide tylosin that has marketing
authorizations for the treatment and prevention of BRD and
treatment and metaphylaxis of SRD (EMA, 2011; Rose et al.,
2016). The pharmacokinetic characteristics of tildipirosin have
been studied in cattle and pigs (Menge et al., 2012; Rose et al.,
2013; Torres et al., 2016). This macrolide is rapidly absorbed and
extensively distributed to the site of respiratory infection followed
by slow elimination. Clinical efficacy has been demonstrated for
tildipirosin in cattle and swine clinical field trials (EMA, 2011;
Bartram et al., 2016; Confer et al., 2016; Teixeira et al., 2017).
The MIC90 values of tildipirosin against bacterial pathogens most
commonly associated with BRD were determined as 1 µg/mL
for M. haemolytica and P. multocida and 4 µg/mL for H. somni
in different European countries (EMA, 2011). However, the
pharmacokinetic/pharmacodynamic (PK/PD) index that best
correlates with the efficacy of tildipirosin remains undefined.
For macrolides such as tulathromycin, gamithromycin, and
tildipirosin, good clinical efficacy and bacteriological cure are
commonly achievable with plasma concentrations that are lower,
even much lower, than in vitro MICs for major lung pathogens
(Nowakowski et al., 2004; Huang et al., 2010; Menge et al.,
2012; Toutain et al., 2017). Recently, it has been shown that
free tulathromycin concentrations in serum suffice to explain
the efficacy of single-dose tulathromycin in clinical use and a
rational dosage regimen can be computed for macrolides (e.g.,
tulathromycin) using classical PK/PD concepts (Toutain et al.,
2017).
In the present study, we determined the PK of unbound
tildipirosin in a neutropenic murine lung infection model
infected with P. multocida. We also evaluated the impact of dose
and dosing regimens on the in vivo drug efficacy. The objectives
of our studies were to elucidate the PK/PD index of tildipirosin
that correlates best with efficacy against P. multocida in a murine
lung infection model and to determine the target values of the
PK/PD index to achieve various killing effects.
MATERIALS AND METHODS
Antibiotic and Bacteria
Tildipirosin (40 mg/kg solution for subcutaneous injection)
was obtained from HVSEN Biotechnology (Hubei, China).
Tildipirosin (99.9% purity) was purchased from Sigma-Aldrich
(St. Louis, MO, United States). P. multocida strain CVCC1669
(type B, serotype 2) was purchased from the China Veterinary
Culture Collection Center (Beijing, China). The organism was
grown, sub-cultured and quantified in Mueller-Hinton Broth
(Becton Dickinson, Sparks, MD, United States) and Tryptic
Soy Agar (Huankai, Guangzhou, China) supplemented with
5% defibrinated sheep blood (Puboxin Biotechnology, Beijing,
China).
Animals
Six-week-old, specific-pathogen-free (SPF), female ICR mice
(weight: 22–24 g) were purchased from Guangdong Medical
Laboratory Animal Center (Guangzhou, China). The mice were
acclimatized for 1 week under SPF environmental conditions
(20∼26◦C, 40–70% relative humidity) before the experiment
in the Laboratory Animal Center of South China Agricultural
University (Guangzhou, China). The mice were supplied with
SPF feed and water ad libitum. All procedures were approved
by the Institutional Animal Care and Use Committee (IACUC)
of South China Agricultural University (Approval No. 2016-
A028) and were in accordance with the American Association for
Accreditation of Laboratory Animal Care (AAALAC) guidelines.
In Vitro Susceptibility Testing
The minimum inhibitory concentration (MIC) of tildipirosin
against P. multocida CVCC1669 was determined in serum by
broth microdilution methodology according to the Clinical and
Laboratory Standards Institute (CLSI) recommended methods
and quality control requirements. Susceptibility testing was
performed in triplicates and mean value of MIC was used for data
analysis.
Murine Lung Infection Model
Neutropenia (neutrophils, ≤100 mm3) was induced via
intraperitoneal injections of cyclophosphamide (Aladdin,
Shanghai, China) for 4 days at 150 mg/kg of body weight and for
one more day at 100 mg/kg of body weight prior to experimental
infection. Lung infection was produced by using an intratracheal
injection of 50 µL of an early-logarithmic-phase bacterial
suspension [∼108 colony forming units (CFUs)/mL] with a
tracheal cannula under anesthesia with pentobarbital sodium
as previously described (Dudhani et al., 2010; Qu et al., 2015).
The bacterial suspension was introduced through the glottis via
a 22G “Y” type intravenous catheter. When the catheter was
successfully inserted into the trachea, the bacterial suspension
was injected instantaneously. Thereafter, the animals were held
in a vertical position for 15 s. Tildipirosin treatment commenced
2 h after inoculation, when an infection was reproducibly
established (bacterial burden was 5.91± 0.56 log10CFU/lung).
Pharmacokinetics of Tildipirosin in
Neutropenic Infected Mice
Single-dose PK studies of tildipirosin were performed with
neutropenic lung-infected mice following subcutaneous
administration (dose volume: 0.2 mL) of tildipirosin (1, 2, 4, 6,
and 8 mg/kg). The sedation/analgesic procedure was performed
by placing animals in an induction chamber with oxygen flow rate
at 0.5–1.0 L/min and isoflurane vapor flow rate at approximately
3–5% for induction and then at approximately 1–3% for
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maintenance. Blood was sampled by retro-orbital puncture and
placed into heparinized tubes per dose level at 0.033, 0.083, 0.167,
0.25, 1, 2, 4, 8, 12, 24, 36, 48 h after drug administration (n = 4
animals per time point). Individual animals were sampled three
or four times. The total volume collected from individual animals
was less than 10% of the total blood volume. The samples were
centrifuged at 3,000 g for 10 min at 4◦C and the plasma was
stored at −80◦C until analysis. The concentration of tildipirosin
in each plasma sample was determined by a validated liquid
chromatography–tandem mass spectrometry (LC–MS/MS)
method (Rose et al., 2013), with minor modifications. Plasma
samples (0.1 mL) were deproteinized with 0.45 mL acetonitrile
followed by centrifugation at 3,300 g for 10 min at 4◦C. The
supernatants (0.2 mL) were transferred into glass tubes and
diluted with 0.6 mL ultrapure water. The calibration range was
0.01–5 µg/mL. The intraday and interday precision levels varied
from 1.9 to 6.1% and from 2.6 to 4.8%, respectively. The limit of
detection (LOD) and limit of quantification (LOQ) were 0.005
and 0.01 µg/mL, respectively.
The values of unbound tildipirosin plasma PK parameters in
the single-dose PK studies were obtained by non-compartmental
analysis in Phoenix WinNonlin R© 7.0 (Certara, L.P., Princeton,
NJ, United States). The following parameters (referenced to the
protein binding of 17% in plasma as previously described) (EMA,
2010), including the elimination half-life (t1/2), the area under
concentration-time curve from 0 to 24 h (fAUC0−24 h), the
peak drug concentration (fCmax), and the time of maximum
concentration (fTmax) were calculated. The corresponding
unbound plasma concentration-time profiles after multiple
dosage regimens were predicted using Phoenix’s non-parametric
superposition function based on the single-dose unbound plasma
PK concentration-time profile.
Pharmacodynamics of Tildipirosin in
Neutropenic Mouse Lung Infection
Model
Neutropenic mice were infected with P. multocida CVCC 1669
2 h prior to the initiation of treatment. Group of two mice were
treated for 24 h with 20 dose regimens included five dose levels
(1, 2, 4, 6, and 8 mg/kg) administered subcutaneously using
four dosing intervals (every 6, 8, 12, and 24 h). Total dose of
tildipirosin ranged of 1–32 mg/kg/24 h. The mice were sacrificed
after 24 h of therapy, and the lung samples were aseptically
removed and homogenized for CFU determination. Untreated
control mice were sacrificed before tildipirosin treatment and at
24 h after treatment.
Data Analysis
The PK/PD analysis was conducted using the inhibitory effect
Imax model (Riviere and Toutain, 2011). This model is described
by the following equation:
E = Eo − Imax · XIC50 + X
Where E is the antibacterial effect, measured as change in
log10CFU/lung after 24 h of treatment, compared with the
initial log10CFU/lung in the untreated control mice; E0 is the
difference in number of bacteria (log10CFU/lung) in control
samples between time 0 and 24 h. Imax is the maximum
antimicrobial growth inhibition determined as the change in
log10CFU/lung after 24 h treatment with tildipirosin. X is the
predictive variable (express as fAUC0−24 h/MIC, fCmax/MIC,
and f%T > MIC), IC50 is the X value producing 50% of
the maximum antibacterial effect. The relationship between
efficacy and the three PK/PD indices was determined by non-
linear least-squares regression in Phoenix WinNonlin R© PD
model. The coefficient of determination (R2) was used to
estimate the variance due to regression for each of the PK/PD
indices.
RESULTS
In Vitro Susceptibility Testing
The average MIC of tildipirosin against P. multocida CVCC 1669
in serum was 0.25 µg/mL.
Pharmacokinetics of Tildipirosin in
Neutropenic Infected Mice
The unbound plasma tildipirosin concentration-time
courses in neutropenic infected mice following single
subcutaneous injection at 1, 2, 4, 6, and 8 mg/kg are
shown in Figure 1. The plasma protein binding of 17%
was employed to generate the corresponding time course
profiles for unbound plasma tildipirosin, and the derived
values of PK parameters are presented in Table 1. The
fAUC0−24 h and fCmax for the escalating single doses
were increased in a dose-dependent manner, ranging
from 0.49 to 4.14 µg·h/mL and 0.30 to 2.99 µg/mL,
respectively. The elimination half-life ranged from 13.67 to
38.25 h.
FIGURE 1 | Unbound plasma tildipirosin concentration-time courses in
neutropenic infected mice following single subcutaneous injections of 1, 2, 4,
6, and 8 mg/kg.
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TABLE 1 | Pharmacokinetic parameters for unbound plasma tildipirosin
concentrations following single subcutaneous injections (1–8 mg/kg) in
neutropenic infected mice.
Parameter Single subcutaneous injection level
1 mg/kg 2 mg/kg 4 mg/kg 6 mg/kg 8 mg/kg
fCmax (µg/mL) 0.30 0.60 1.16 1.84 2.99
fTmax (h) 0.17 0.08 0.08 0.08 0.08
T1/2 (h) 23.03 38.25 26.40 13.67 32.56
fAUC0−24 h
(µg·h/mL)
0.49 1.00 1.71 2.54 4.14
fCmax: the peak unbound plasma tildipirosin concentration; fTmax: the time of
maximum unbound plasma tildipirosin concentration; T1/2: half-life; fAUC0−24 h:
the area under unbound plasma tildipirosin concentration-time curve over 24 h.
Relationships Between PK/PD Indices
and Antibacterial Activity
At the start of tildipirosin therapy, the bacterial burdens
were 5.91 ± 0.56 log10CFU/lung. In untreated animals, the
organisms grew at a rate of 3.79 ± 0.07 log10CFU/lung over
the next 24 h. The most effective tildipirosin dosage regimens
result in reductions, relative to the bacterial number at the
start of tildipirosin treatment, of 2.24 ± 0.21 log10CFU/lung.
The relationships between the effect of tildipirosin against
P. multocida and each of the PK/PD indices in the lung
infection model are shown in Figure 2. The strongest
relationships were observed when results were correlated with the
fAUC0−24 h/MIC, with R2 value of 0.911 (fCmax/MIC R2, 0.824;
f%T > MIC R2, 0.894). The fAUC0−24 h/MIC ratios required for
the various efficacy targets in the lung infection model are shown
in Table 2.
DISCUSSION
Previous studies have shown that tildipirosin administered by
single subcutaneous administration to cattle and pigs exhibits
high bioavailability, rapid distribution to lung, and a long
TABLE 2 | The PK/PD parameter estimates for the fAUC0−24 h/MIC index and the
fAUC0−24 h/MIC values required for various antibacterial effects.
Parameter Mean ± SD
E0 (log10CFU/lung) 4.16 ± 0.43
Imax (log10CFU/lung) 8.66 ± 1.10
IC50 21.57 ± 8.38
fAUC0−24 h/MIC for bacteriostatic action 19.93 h
fAUC0−24 h/MIC for 1 log10 kill 31.89 h
fAUC0−24 h/MIC for 2 log10 kill 53.27 h
elimination half-life to provide therapeutic or preventive
efficacy against BRD and SRD (EMA, 2011; Menge et al.,
2012; Rose et al., 2013). These earlier studies suggest that
further research is needed to gain deeper insights into the
PK/PD relationship of tildipirosin. In the present study,
we used a murine lung infection model to determine, for
the first time in vivo, the PK/PD indices best predictive
of activity against P. multocida and the magnitude of the
predictive indices required for various magnitudes of killing
effect. Consistent with other macrolides (Modric et al.,
1998; Toutain et al., 2017), tildipirosin dose fractionation
experiments demonstrated that the fAUC0−24 h/MIC ratio
was most closely linked to the therapeutic efficacy against
P. multocida.
Following subcutaneous administration, tildipirosin is
rapidly absorbed in mice as demonstrated by the times
reaching maximum plasma concentrations observed at
as early as 5 min after administration in this study,
which was significantly faster than the 23 min observed
in bovine (Menge et al., 2012). Both absorption and
overall exposure to tildipirosin, reflected by fCmax and
fAUC0−24 h, respectively, in P. multocida infected mice
displayed dose proportionality over the dose range from
1 to 8 mg/kg. The non-parametric superposition principle
was applied to the single-dose unbound plasma tildipirosin
concentration-time curves to generate the unbound plasma
concentrations for the multiple dose regimens across the 24 h
FIGURE 2 | Relationships between the effect of tildipirosin against Pasteurella multocida CVCC 1669 and the PK/PD indices fAUC0−24 h/MIC (A), fCmax/MIC (B),
and f%T > MIC (C) in the murine lung infection model. Each symbol represents the datum from a single lung. R2 is the coefficient of determination.
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treatment period. The non-parametric superposition principle
was based on the following assumptions: (1) each dose of a drug
acts independently of every other dose; (2) the rate and extent
of absorption and average systemic clearance are the same for
each dosing interval; and (3) linear pharmacokinetics apply so
that a change in dose during the multiple dosing regimen can be
accommodated.
MIC90 values of tildipirosin against the pathogens most
commonly involved in the etiology of BRD were determined as
1 µg/mL for M. haemolytica and P. multocida and 4 µg/mL
for H. somni under standard CLSI testing conditions in
epidemiologically unrelated bovine isolates (wild-type) collected
in different European countries (EMA, 2011). Clinical efficacy
has been demonstrated for tildipirosin in cattle and swine
clinical field trials. However, similar to other macrolides such
as tulathromycin, gamithromycin, and tilmicosin, the plasma
concentration of tildipirosin after single intramuscular injection
at 4 mg/kg body weight is clearly below the in vitro MIC90
levels for major lung pathogens (Shryock et al., 1996; Modric
et al., 1998; Benchaoui et al., 2004; Nowakowski et al., 2004;
Godinho, 2008; Huang et al., 2010). The described at least
fourfold reduction in A. pleuropneumoniae MICs appears to be
a conservative correction for in vitro activity when interpreting
tildipirosin activity for in vivo pH and serum situations in swine
(Rose et al., 2013). The in vitro susceptibility of Macrolides
and ketolides show a considerable enhancement of antimicrobial
activity against P. aeruginosa in RPMI 1640 medium and
other eukaryotic media through increased uptake and reduced
eﬄux (Buyck et al., 2012). More recently, the P. aeruginosa
became susceptible when tested in a eukaryotic medium rather
than a conventional broth, suggesting that measuring MICs
in RPMI-1640 could be easily implemented to phenotypically
detect acquired resistance to macrolides in P. aeruginosa from
cystic fibrosis patients (Mustafa et al., 2017). Therefore, the
crucial proviso is that MICs have to be determined in serum
instead of artificial medium such as Mueller-Hinton broth, when
establishing PK/PD relationships as a basis for macrolide dosage
determination and prevention of resistance emergence (Lees
et al., 2006; Toutain et al., 2017).
The PK/PD analysis revealed that fAUC0−24 h/MIC was the
PK/PD index that was the most predictive of the antibacterial
effect of tildipirosin against P. multocida. In our models,
the fAUC0−24 h/MIC ratio appeared to be only slightly more
predictive than f%T > MIC of in vivo bacterial killing,
on the basis of the R2 values, although visual examination
of the relationships revealed a relativity large scatter at
fAUC0−24 h/MIC values of 20–40 (Figure 2). While most
macrolides have been classified as time-dependent killing drugs,
best described by the PK/PD parameter time above MIC
(T > MIC), for newer macrolides such as azithromycin and
clarithromycin, the plasma AUC/MIC ratio appears to be the
best correlate with successful outcome (Lees et al., 2006).
Similar observations in regard to the discrimination between
PK/PD indices have been made by use of tissue cage model
with tulathromycin (Toutain et al., 2017; Zhou et al., 2017).
Those studies indicate that free tulathromycin concentrations in
serum suffice to explain the efficacy of single-dose tulathromycin
in clinical use and a dosage regimen can be computed for
tulathromycin using traditional PK/PD concepts. DeDonder et al.
(2016) investigated PK/PD of gamithromycin in pulmonary
epithelial lining fluid (PELF) in naturally occurring BRD in
multisource commingled feedlot cattle. The findings from that
study indicate that PK/PD indices were predictive of positive
treatment outcomes and a significant association was found
between treatment success and PELF AUC0−24 h/MIC for
P. multocida.
CONCLUSION
This study is the first to demonstrate in murine lung infection
model that fAUC0−24 h/MIC is the PK/PD index that is
the most strongly linked to the antibacterial effect, and we
determined the fAUC0−24 h/MIC targets in plasma for achieving
various magnitudes of bacterial kill. Our study provides key
pharmacological information for optimized clinical use of
tildipirosin against infections caused by P. multocida.
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